JP2008500399A5 - - Google Patents

Download PDF

Info

Publication number
JP2008500399A5
JP2008500399A5 JP2007527564A JP2007527564A JP2008500399A5 JP 2008500399 A5 JP2008500399 A5 JP 2008500399A5 JP 2007527564 A JP2007527564 A JP 2007527564A JP 2007527564 A JP2007527564 A JP 2007527564A JP 2008500399 A5 JP2008500399 A5 JP 2008500399A5
Authority
JP
Japan
Prior art keywords
immunogenic composition
protein
nucleic acid
heterologous nucleic
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007527564A
Other languages
English (en)
Japanese (ja)
Other versions
JP4896021B2 (ja
JP2008500399A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/018225 external-priority patent/WO2006078294A2/en
Publication of JP2008500399A publication Critical patent/JP2008500399A/ja
Publication of JP2008500399A5 publication Critical patent/JP2008500399A5/ja
Application granted granted Critical
Publication of JP4896021B2 publication Critical patent/JP4896021B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007527564A 2004-05-21 2005-05-20 呼吸器系病原体ワクチンのためのアルファウイルスベクター Expired - Lifetime JP4896021B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US57343304P 2004-05-21 2004-05-21
US60/573,433 2004-05-21
US64373705P 2005-01-12 2005-01-12
US60/643,737 2005-01-12
PCT/US2005/018225 WO2006078294A2 (en) 2004-05-21 2005-05-20 Alphavirus vectors for respiratory pathogen vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008125258A Division JP2008266341A (ja) 2004-05-21 2008-05-12 呼吸器系病原体ワクチンのためのアルファウイルスベクター

Publications (3)

Publication Number Publication Date
JP2008500399A JP2008500399A (ja) 2008-01-10
JP2008500399A5 true JP2008500399A5 (https=) 2008-06-26
JP4896021B2 JP4896021B2 (ja) 2012-03-14

Family

ID=36692669

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007527564A Expired - Lifetime JP4896021B2 (ja) 2004-05-21 2005-05-20 呼吸器系病原体ワクチンのためのアルファウイルスベクター
JP2008125258A Pending JP2008266341A (ja) 2004-05-21 2008-05-12 呼吸器系病原体ワクチンのためのアルファウイルスベクター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008125258A Pending JP2008266341A (ja) 2004-05-21 2008-05-12 呼吸器系病原体ワクチンのためのアルファウイルスベクター

Country Status (6)

Country Link
US (3) US20090104226A1 (https=)
EP (3) EP2848692B1 (https=)
JP (2) JP4896021B2 (https=)
CA (1) CA2567446C (https=)
ES (1) ES2647491T3 (https=)
WO (1) WO2006078294A2 (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5689576B2 (ja) 2004-05-25 2015-03-25 ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド αウイルスレプリコンパッケージング構築物
EP2591114B1 (en) 2010-07-06 2016-06-08 GlaxoSmithKline Biologicals SA Immunisation of large mammals with low doses of rna
ES2646669T3 (es) 2010-07-06 2017-12-14 Glaxosmithkline Biologicals Sa Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
ES2557382T3 (es) 2010-07-06 2016-01-25 Glaxosmithkline Biologicals Sa Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
MX342608B (es) 2010-07-06 2016-10-06 Novartis Ag * Particulas de suministro similares a viriones para moleculas de arn de autorreplicacion.
LT4226941T (lt) 2010-08-31 2025-01-10 Glaxosmithkline Biologicals Sa Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui
SI4043040T1 (sl) 2010-08-31 2023-04-28 Glaxosmithkline Biologicals Sa Mali liposomi za dostavo imunogen-kodirajoče RNA
WO2012051211A2 (en) 2010-10-11 2012-04-19 Novartis Ag Antigen delivery platforms
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
EP2714076A1 (en) * 2011-05-26 2014-04-09 GlaxoSmithKline Biologicals S.A. Inactivated dengue virus vaccine
RU2013154295A (ru) 2011-06-08 2015-07-20 Шир Хьюман Дженетик Терапис, Инк. КОМПОЗИЦИИ ЛИПИДНЫХ НАНОЧАСТИЦ И СПОСОБЫ ДЛЯ ДОСТАВКИ мРНК
ES2795110T3 (es) 2011-06-08 2020-11-20 Translate Bio Inc Lípidos escindibles
EP4115875A1 (en) 2011-07-06 2023-01-11 GlaxoSmithKline Biologicals S.A. Liposomes having useful n:p ratio for delivery of rna molecules
EP2729165B1 (en) 2011-07-06 2017-11-08 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
MX366055B (es) * 2011-08-31 2019-06-26 Novartis Ag Liposomas pegilados para admistracion de acido ribonucleico (arn) que codifica para inmunogeno.
RU2014118727A (ru) * 2011-10-11 2015-11-20 Новартис Аг Рекомбинантные самореплицирующиеся полицистронные молекулы рнк
CN104023744A (zh) * 2011-12-23 2014-09-03 诺华股份有限公司 用于针对金黄色葡萄球菌免疫的稳定组合物
BR112015003074A2 (pt) 2012-08-17 2017-07-04 Intervet Int Bv composição, vacina para proteger um animal contra uma infecção com bactérias leptospira, e, uso de ácido etilenodiaminatetra-acético.
WO2014043518A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
MX384992B (es) 2014-06-13 2025-03-14 Glaxosmithkline Biologicals Sa Combinaciones inmunógenas.
BR112017026523A2 (pt) 2015-06-12 2018-08-14 Glaxosmithkline Biologicals Sa vetor recombinante, adenovírus recombinante, composição, uso de um vetor recombinante, de um adenovírus recombinante ou de uma composição, método para induzir uma resposta imune em um indivíduo, e, polinucleotídeo isolado.
EP4137150A1 (en) 2015-08-03 2023-02-22 The United States of America, as represented by the Secretary, Department of Health and Human Services Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use
BR112018014109A2 (en) 2016-01-11 2018-12-11 Verndari, Inc. microneedle compositions and methods of using them
WO2017162265A1 (en) * 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
US12508308B2 (en) * 2016-05-04 2025-12-30 CureVac SE Influenza mRNA vaccines
WO2018107088A2 (en) * 2016-12-08 2018-06-14 Modernatx, Inc. Respiratory virus nucleic acid vaccines
WO2018147802A1 (en) 2017-02-07 2018-08-16 Agency For Science, Technology And Research Alphavirus nsp mutants as vaccines
EP3634449A4 (en) 2017-05-08 2021-03-17 Gritstone Oncology, Inc. ALPHAVIRUS NEOANTIGEN VECTORS
WO2019121513A1 (en) * 2017-12-18 2019-06-27 Intervet International B.V. Swine influenza a virus vaccine
BR112020012361A2 (pt) 2017-12-20 2020-11-24 Glaxosmithkline Biologicals S.A. constructos de antígeno do vírus epstein-barr
CN111315407B (zh) 2018-09-11 2023-05-02 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
WO2020076775A1 (en) * 2018-10-08 2020-04-16 Janssen Pharmaceuticals, Inc. Alphavirus-based replicons for administration of biotherapeutics
AU2019374874A1 (en) * 2018-11-07 2021-06-10 Gritstone Bio, Inc. Alphavirus neoantigen vectors and interferon inhibitors
NL2022538B1 (en) 2019-02-08 2020-08-19 Academisch Ziekenhuis Groningen Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof.
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
AU2021236068A1 (en) 2020-03-09 2022-10-06 Arcturus Therapeutics, Inc. Compositions and methods for inducing immune responses
IT202000009625A1 (it) * 2020-04-30 2021-10-30 Takis S R L Polinucleotidi codificanti antigeni di sars-cov-2 e relativo uso in campo medico come vaccini.
US20230355741A1 (en) 2020-05-11 2023-11-09 Intervet Inc. Feline Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine
CA3170740A1 (en) * 2020-05-29 2021-12-02 Curevac Ag Nucleic acid based combination vaccines
BR112022025678A2 (pt) * 2020-06-19 2023-01-17 Intervet Int Bv Vacina contra o vírus da influenza a suína compreendendo duas partículas de replicon de rna distintas
EP4168429A1 (en) * 2020-06-19 2023-04-26 Intervet International B.V. Swine influenza a virus vaccine comprising a nucleic acid construct comprising first, second and third nucleic acid sequences encoding distinct neuraminidase antigens of the virus
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒
EP4196128A4 (en) 2020-08-14 2024-06-12 Arcturus Therapeutics, Inc. METHOD FOR FREEZE DILIZATION OF LIPID NANOPARTICLES
BR112023004123A2 (pt) * 2020-09-07 2023-04-04 Intervet Int Bv Vacina de haste da ha para alvos positivos de anticorpos de ha
WO2022087006A1 (en) * 2020-10-20 2022-04-28 George Mason Research Foundation, Inc. Hybrid alphavirus-sars-cov-2 particle and methodology of making and using same
MX2023005495A (es) 2020-11-12 2023-05-23 Intervet Int Bv Vectores recombinantes que codifican para proteinas espiculares quimericas del coronavirus y uso de los mismos.
KR20230120646A (ko) * 2020-12-02 2023-08-17 세퀴러스 인코포레이티드 멀티시스트론성 rna 백신 및 이의 용도
US11918643B2 (en) 2020-12-22 2024-03-05 CureVac SE RNA vaccine against SARS-CoV-2 variants
AU2022210420A1 (en) * 2021-01-19 2023-09-07 Seattle Project Corp. Modified alphavirus vectors
CN112899301B (zh) * 2021-01-29 2023-04-11 中国热带农业科学院热带生物技术研究所 一种木薯普通花叶病毒诱导的基因沉默系统及其应用
US20220249651A1 (en) * 2021-02-01 2022-08-11 Aegle Biotech Universal vaccines against immunogens of pathogenic organisms that provide organism-specific and cross-group protection
JP2024514182A (ja) * 2021-04-13 2024-03-28 モデルナティエックス インコーポレイテッド 呼吸器ウイルス組み合わせワクチン
US20220401548A1 (en) * 2021-06-17 2022-12-22 National Yang Ming Chiao Tung University Sindbis virus dna-based vaccine
EP4448770A4 (en) * 2021-12-17 2025-12-17 Vlp Therapeutics Japan Inc EFFICIENT VACCINE
CN116554341A (zh) * 2022-01-29 2023-08-08 中国疾病预防控制中心病毒病预防控制所 一种人偏肺病毒病毒样颗粒、制备方法、应用及疫苗
EP4608442A1 (en) 2022-10-28 2025-09-03 GlaxoSmithKline Biologicals S.A. Nucleic acid based vaccine

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360897A (en) 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
AU631377B2 (en) 1988-08-25 1992-11-26 Liposome Company, Inc., The Affinity associated vaccine
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
JPH09500128A (ja) 1993-07-15 1997-01-07 ミネソタ マイニング アンド マニュファクチャリング カンパニー イミダゾ〔4,5−c〕ピリジン−4−アミン
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
DK0814154T3 (da) 1993-09-15 2009-08-31 Novartis Vaccines & Diagnostic Rekombinante alfavirusvektorer
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
FR2726003B1 (fr) 1994-10-21 2002-10-18 Agronomique Inst Nat Rech Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
FR2737730B1 (fr) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
AU2800797A (en) 1996-04-05 1997-10-29 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US5842723A (en) 1996-11-25 1998-12-01 Burex Automotive America, Inc. Flexible connection arrangement for connecting a pipe of an exhaust system to an engine, especially in a motor vehicle
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
US6060308A (en) 1997-09-04 2000-05-09 Connaught Laboratories Limited RNA respiratory syncytial virus vaccines
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
CA2309826A1 (en) 1997-11-14 1999-05-27 Connaught Laboratories Limited Alphavirus vectors for paramyxovirus vaccines
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
WO2000018929A2 (en) * 1998-09-25 2000-04-06 Smithkline Beecham Biologicals S.A. Paramyxovirus vaccines
KR100629028B1 (ko) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
US6329201B1 (en) 1998-12-31 2001-12-11 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
US6242259B1 (en) 1998-12-31 2001-06-05 Chiron Corporation Compositions and methods for packing of alphavirus vectors
DE60044125D1 (de) 1999-04-14 2010-05-20 Novartis Vaccines & Diagnostic Zusammensetzungen und verfahren zur auslösung einer immunantwort auf basis alphavirus-vektoren-systeme
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
HUP0202885A3 (en) 1999-09-24 2004-07-28 Smithkline Beecham Biolog Vaccines
TR200200777T2 (tr) 1999-09-24 2002-09-23 Smithkline Beecham Biologicals S.A. Polioksietilen alkil eteri veya esteriyle en az bir iyonik olmayan yüzey aktif maddeli adjuvant.
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
US20010044416A1 (en) 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
WO2001081609A2 (en) * 2000-03-22 2001-11-01 Chiron Corporation Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
ES2319864T3 (es) * 2000-04-28 2009-05-14 St. Jude Children's Research Hospital Sistema de transfeccion de adn para la generacion de virus infecciosos de arn de cadena negativa.
US6767699B2 (en) 2000-05-31 2004-07-27 Chiron Corporation Method for the quantitation of alphavirus replicon particles
MXPA02012254A (es) * 2000-06-23 2003-04-25 American Cyanamid Co Montaje de particulas quimericas semejantes al virus de influenza y del tipo silvestre.
AU2001294750C1 (en) 2000-09-26 2008-09-18 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
KR20020059856A (ko) * 2001-01-08 2002-07-16 김철중 에이치아이브이 유사입자의 제조
CA2434546C (en) * 2001-01-12 2012-09-11 Chiron Corporation Induction of immune response by a replication-defective venezuelan equine encephalitis-sindbis chimeric virus replicon particle encoding an antigen
JP4608210B2 (ja) * 2001-05-31 2011-01-12 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド キメラアルファウイルスレプリコン粒子
ES2330202T5 (es) 2001-09-06 2014-01-20 Alphavax, Inc. Sistemas vectores basados en replicones de alfavirus
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
CA2492823A1 (en) 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
FR2832423B1 (fr) 2001-11-22 2004-10-08 Vivalis Systeme d'expression de proteines exogenes dans un systeme aviaire
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
WO2004000872A2 (en) * 2002-06-21 2003-12-31 University Of North Carolina At Chapel Hill Improved alphavirus vectors having attenuated virion structural proteins
US20040208848A1 (en) * 2002-12-13 2004-10-21 Smith Jonathan F. Multi-antigenic alphavirus replicon particles and methods
US7521062B2 (en) 2002-12-27 2009-04-21 Novartis Vaccines & Diagnostics, Inc. Thiosemicarbazones as anti-virals and immunopotentiators
CA2513655C (en) 2003-01-21 2011-11-22 Chiron Corporation Use of tryptanthrin compounds for immune potentiation
US7442381B2 (en) 2003-03-20 2008-10-28 Alphavax, Inc. Alphavirus replicons and helper constructs
ES2529736T3 (es) * 2003-04-10 2015-02-25 Novartis Vaccines And Diagnostics, Inc. Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS
KR20060017635A (ko) * 2003-06-05 2006-02-24 와이어쓰 홀딩스 코포레이션 베네쥬엘라 말 뇌염 바이러스 레플리콘 벡터 및파라믹소바이러스 단백질 항원을 포함하는 면역원성 조성물
DE602004021260D1 (de) * 2003-07-11 2009-07-09 Alphavax Inc Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren

Similar Documents

Publication Publication Date Title
JP2008500399A5 (https=)
US20240075125A1 (en) Expression systems
CN108348593B (zh) 基于人呼吸道合胞病毒(hrsv)病毒样颗粒(vlps)的疫苗
WO2003072719A3 (en) Metapneumovirus strains and their use in vaccine formulations and as vector for expression of antigenic sequences
JP2013518052A5 (https=)
WO2014205579A4 (en) Modified matrix proteins of vesicular stomatitis virus
NO20082149L (no) Hundeinfluensavirus og relaterte sammensetninger og fremgangsmater for bruk
ATE419369T1 (de) Chimäre mensch-rinder respiratory syncytial virus vakzinen
JP2014507146A5 (https=)
BR0312173A (pt) Mólecula de cdna, molécula e sequência de cdna recombinante, vetor, processo de preparação de partìculas de vìrus do sarampo infeccioso, composição imunogênica, composição de vacina e vìrus mononegaviral recombinante
JP5675789B2 (ja) 免疫接種のための発現ベクターとしての水疱性口内炎ウイルスの異なる複数の抗原型
CA2835967A1 (en) Papaya mosaic virus compositions and uses thereof for stimulation of the innate immune response
JP2009511080A5 (https=)
CN103228293A (zh) 用于在哺乳动物中预防和治疗金迪普拉病毒感染的疫苗制剂
CN101899461B (zh) 一种编码甲型流感病毒NP蛋白和M2e多肽的融合基因
Tomčíková et al. Different mechanisms of the protection against influenza A infection mediated by broadly reactive HA2-specific antibodies
US20160120974A1 (en) Semi-live respiratory syncytial virus vaccine
CN107961371A (zh) 季节流感-rsv联合疫苗及其制备方法和应用
Hnuma et al. Characteristics of Cytotoxic T Lymphocytes Directed to Influenza Virus Haemagglutinin Elicited by Immunization with Muramyldipeptide‐Influenza Liposome Vaccine
CN103316357A (zh) 携带rsv基因的重组流感病毒嵌合疫苗及其制备方法
US20160346378A1 (en) Semi-live respiratory syncytial virus vaccine
JP7651129B2 (ja) ウイルスの非構造タンパク質が担持された複合タンパク質単量体、当該単量体の会合体、及び当該会合体を有効成分とするコンポーネントワクチン
KR20240011134A (ko) Rsv 및 piv3 감염을 예방하기 위한 조성물 및 방법
HUT54732A (en) Process for producing vaccine polypeptides
CN102174090B (zh) 一种猪源a型流感病毒头部蛋白及其制备方法和应用